Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
07 nov. 2024 16h05 HE
|
Assembly Biosciences, Inc.
Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral...
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
23 sept. 2024 08h00 HE
|
Assembly Biosciences, Inc.
– ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days – – Half-life of approximately 20 days supports once-weekly or once-monthly oral dosing; both...
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
08 août 2024 16h05 HE
|
Assembly Biosciences, Inc.
Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Phase 1a first-in-human data expected in Q3 2024 and interim Phase 1b data in...
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
15 juil. 2024 08h00 HE
|
Assembly Biosciences, Inc.
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data...
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
18 juin 2024 08h00 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases,...
Assembly Biosciences Announces $12.6 Million in Equity Financings
17 juin 2024 08h00 HE
|
Assembly Biosciences, Inc.
— Funding supports advancement of antiviral portfolio, including four candidates in clinical development, and extends cash runway into Q1 2026 — — Anticipated near term interim data read outs include...
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
10 juin 2024 08h00 HE
|
Assembly Biosciences, Inc.
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 – – Phase 1b study portion of multiple...
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
05 juin 2024 08h00 HE
|
Assembly Biosciences, Inc.
-- Poster highlights promising preclinical profile of ABI-6250 ahead of entry into the clinic, expected by end of 2024 -- SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Assembly...
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
22 mai 2024 08h00 HE
|
Assembly Biosciences, Inc.
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio’s long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at...
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
08 mai 2024 16h05 HE
|
Assembly Biosciences, Inc.
Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on...